Carlos H. Barrios

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Martine Piccart, Marion Procter, Brian Leyland‐Jones et al. · New England Journal of Medicine · 2005 · 5.1K citations · Full text

Medicine, Oncology, Pharmacology +16

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp et al. · The Lancet · 2016 · 4.8K citations · Full text

Medicine, Oncology, Pharmacology +13

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Nizar M. Tannir, Osvaldo Arén Frontera et al. · New England Journal of Medicine · 2018 · 4.6K citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Peter Schmid, Sylvia Adams, Hope S. Rugo et al. · New England Journal of Medicine · 2018 · 4.4K citations · Full text

Medicine, Oncology, Pharmacology +17

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15